Skip to main content
eScholarship
Open Access Publications from the University of California

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.

  • Author(s): Coleman, Robert L
  • Sill, Michael W
  • Bell-McGuinn, Katherine
  • Aghajanian, Carol
  • Gray, Heidi J
  • Tewari, Krishnansu S
  • Rubin, Steven C
  • Rutherford, Thomas J
  • Chan, John K
  • Chen, Alice
  • Swisher, Elizabeth M
  • et al.
Main Content
Current View